UroGen Pharma Ltd.
HealthcareNASDAQ:URGN · NASDAQ Global Market
+$0.22 today
Vol 0.58M · Avg 0.80M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$140.5M of revenue converted into -$133.2M of net income for the selected period. Gross margin is 89.1% and net margin is -110.9%, showing how much revenue survives after costs and taxes. EPS is $-2.75, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $109.8M +21.4% | $90.4M +9.3% | $82.7M +28.5% | $64.4M +34.0% | $48.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $12.4M +40.2% | $8.9M -5.1% | $9.4M +22.3% | $7.7M +48.4% | $5.2M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $97.3M +19.4% | $81.5M +11.1% | $73.4M +29.4% | $56.7M +32.2% | $42.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 88.7% -1.5pp | 90.2% +1.5pp | 88.7% +0.6pp | 88.1% -1.2pp | 89.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $67.1M +17.4% | $57.1M +25.3% | $45.6M -13.8% | $52.9M +11.0% | $47.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $155.1M | $0 -100.0% | $93.3M +12.6% | $82.8M | $0 | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $222.2M +24.6% | $178.3M +28.4% | $138.9M +2.3% | $135.7M +0.4% | $135.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.4M +632.8% | $329.0K -80.7% | $1.7M -6.2% | $1.8M +118.7% | $831.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$135.7M -42.3% | -$95.4M -58.0% | -$60.4M +20.8% | -$76.2M +29.8% | -$108.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -123.6% -18.1pp | -105.5% -32.5pp | -73.0% +45.5pp | -118.4% +107.5pp | -225.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$124.9M -29.0% | -$96.8M -47.7% | -$65.5M +17.1% | -$79.0M +14.4% | -$92.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -113.7% -6.7pp | -107.1% -27.8pp | -79.2% +43.6pp | -122.8% +69.3pp | -192.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $6.0M -33.0% | $8.9M +237.0% | $2.6M +181.6% | $938.0K +157.0% | $365.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $33.8M +170.3% | $12.5M -14.9% | $14.7M +74.4% | $8.4M | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$28.6M -4.7% | -$27.3M +16.9% | -$32.8M -13.1% | -$29.0M -69.7% | -$17.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$153.4M -23.7% | -$124.0M -26.2% | -$98.3M +9.0% | -$108.0M +1.2% | -$109.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -139.7% -2.5pp | -137.2% -18.3pp | -118.9% +49.0pp | -167.9% +59.8pp | -227.7% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $78.0K -97.2% | $2.8M -27.8% | $3.9M +123.4% | $1.8M +21.1% | $1.4M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$153.5M -21.0% | -$126.9M -24.1% | -$102.2M +6.9% | -$109.8M +0.9% | -$110.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | -139.8% +0.5pp | -140.4% -16.7pp | -123.6% +47.0pp | -170.6% +60.1pp | -230.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 -7.8% | -$3 +16.6% | -$4 +25.9% | -$5 +3.4% | -$5 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 -7.8% | -$3 +16.6% | -$4 +25.9% | -$5 +3.4% | -$5 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $48.1M +12.2% | $42.9M +48.7% | $28.8M +26.4% | $22.8M +2.1% | $22.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $48.1M +12.2% | $42.9M +48.7% | $28.8M +26.4% | $22.8M +2.1% | $22.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
AnaptysBio, Inc.
NASDAQ:ANAB
$2.42B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.80B
Mind Medicine (MindMed) Inc.
MNMD
$1.56B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
Xencor, Inc.
NASDAQ:XNCR
$914.17M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$827.07M
Oculis Holding AG
NASDAQ:OCS
$634.01M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$620.83M
ProKidney Corp.
NASDAQ:PROK
$242.99M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does URGN generate?
UroGen Pharma Ltd. (URGN) reported $109.79M of revenue in fiscal 2025.
Is URGN profitable?
UroGen Pharma Ltd. (URGN) reported -$153,494,000.00 of net income, with a net margin of -139.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.